Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: The pan-american collaborative retina study

Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design: Retrospective, multicenter, interventional, comparative case series. Participants: We reviewed the clinical records of 180 consecutive patients (207 eyes) with subfoveal CNV secondary to AMD at 9 centers from 8 countries. Methods: Patients were treated with at least 1 injection of IVB 1.25 mg (124 eyes [59.9%]) or 2.5 mg (83 eyes [40.1%]). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and 1-, 3-, 6-, 12-, and 24-month visits. Main Outcome Measures: Changes in BCVA and OCT. Results: The mean age of our patients was 74.3±7.5 years. The mean number of IVB injections per eye was 5.1 (range, 124 injections). In the 1.25 mg group, baseline BCVA improved from 20/235 (logarithm of the minimum angle of resolution [logMAR] 1.07) to 20/172 (logMAR 0.92) at 24 months (P less than 0.0001). Similar BCVA changes were observed in the 2.5 mg group. At baseline, the mean central macular thickness (CMT) by OCT in the 1.25 mg group was 308.4±127.52 ?m, which was reduced to 269.35±97.92 ?m, 262.1±94.81 ?m, 264.03±97.06 ?m, 245.91±89.52 ?m, and 249.27±89.14 ?m at 1, 3, 6, 12, and 24 months, respectively (P less than 0.0001). Similar changes were observed in the 2.5 mg group. In the 2.5 mg group, systemic complications included 2 new cases (2.6%) of arterial hypertension, 1 case (1.3%) of stroke, and 1 case (1.3%) of death. Conclusions: Primary IVB at a dose of 1.25 or 2.5 mg seems to provide stability or improvement in BCVA, OCT, and FA in subfoveal CNV secondary to AMD at 24 months. Our results show no significant difference regarding BCVA with IVB at doses of 1.25 or 2.5 mg. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2010 American Academy of Ophthalmology.

• Fecha de publicación: 2010
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/22732
• Acceso en línea: https://doi.org/10.1016/j.ophtha.2010.01.056; https://repository.urosario.edu.co/handle/10336/22732
• Palabra clave: Bevacizumab; Angiogenesis inhibitor; Bevacizumab; Monoclonal antibody; Vasculotropin a; Adult; Aged; Article; Cataract; Drug dose comparison; Drug fatality; Endophthalmitis; Eye examination; Female; Fluorescence angiography; Follow up; Human; Hypertension; Intraocular pressure; Major clinical study; Male; Medical record review; Optical coherence tomography; Priority journal; Retina macula age related degeneration; Retina tear; Retrospective study; Side effect; Stroke; Subretinal neovascularization; Treatment response; Uveitis; Visual acuity; Antagonists and inhibitors; Choroidal neovascularization; Clinical trial; Comparative study; Complication; Injection; Macular degeneration; Middle aged; Multicenter study; Pathophysiology; Physiology; Retina fovea; Time; Very elderly; Vitreous body; Aged; Aged, 80 and over; Angiogenesis inhibitors; Choroidal neovascularization; Female; Fluorescein angiography; Follow-up studies; Fovea centralis; Humans; Injections; Macular degeneration; Male; Middle aged; Retrospective studies; Time factors; Vascular endothelial growth factor a; Visual acuity; Vitreous body; monoclonal; optical coherence; human; monoclonal; humanized; Vegfa protein; Antibodies; Antibodies; Tomography
• License: Abierto (Texto Completo)